Showing results (2831-2840 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|June 28, 2006
Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in GermanyArran T Shearer, Adrian Bagust, Andreas Liebl, et al.Pharmacoeconomics|July 31, 2009
Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysisElise M Pelletier, Boyung Shim, Rami Ben-Joseph, et al.Pharmacoeconomics|March 4, 2009
Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic reviewFawziah Marra, Karine Cloutier, Bridgette Oteng, et al.Pharmacoeconomics|August 12, 2009
Cost effectiveness of fondaparinux in non-ST-elevation acute coronary syndromeJaime Latour-Perez, Eva de-Miguel-BalsaPharmacoeconomics|August 29, 2009
Economic burden of follicular non-Hodgkin's lymphomaTalia Foster, Jeffrey D Miller, Mark E Boye, et al.Pharmacoeconomics|August 29, 2009
The cost of disability and medically related absenteeism among employees with multiple sclerosis in the USJasmina I Ivanova, Howard G Birnbaum, Seth Samuels, et al.Pharmacoeconomics|October 7, 2009
An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UKAgnes Benedict, David A Cameron, Hélène Corson, et al.Pharmacoeconomics|April 10, 2009
Cost-utility analysis of varenicline, an oral smoking-cessation drug, in JapanAtaru Igarashi, Hiroki Takuma, Takashi Fukuda, et al.Pharmacoeconomics|July 10, 2009
Costing infectious disease outbreaks for economic evaluation: a review for hepatitis AJeroen Luyten, Philippe BeutelsPharmacoeconomics|July 10, 2009
Outcomes associated with initial versus later vancomycin use in patients with complicated skin and skin-structure infectionsKamal M F Itani, Kasem S Akhras, Robert Stellhorn, et al.Pageof 336